 NEW YORK, March 04, 2021 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS; Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells UCART, today announced its results for the fourth quarter of 2020, and full year ending December 31, 2020. 